1231952-71-8 Usage
Molecular structure
2-(2-Nitrophenyl)-thiazolo[5,4-b]pyridine-6-Methanol consists of a thiazole ring fused with a pyridine ring, a nitrophenyl group, and a methanol group attached to the sixth carbon atom.
Complex structure
The compound has a unique and intricate arrangement of atoms, which contributes to its potential pharmaceutical applications.
Biological interaction
2-(2-Nitrophenyl)-thiazolo[5,4-b]pyridine-6-Methanol has the ability to interact with biological systems, making it a potential candidate for drug development or research in biochemistry.
Pharmaceutical applications
Due to its unique structure and ability to interact with biological systems, this compound may be useful in the development of new drugs or as a research tool in the field of biochemistry.
Need for further research
To fully understand the potential uses and effects of 2-(2-Nitrophenyl)-thiazolo[5,4-b]pyridine-6-Methanol, additional research is necessary to explore its properties and possible applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1231952-71-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,1,9,5 and 2 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1231952-71:
(9*1)+(8*2)+(7*3)+(6*1)+(5*9)+(4*5)+(3*2)+(2*7)+(1*1)=138
138 % 10 = 8
So 1231952-71-8 is a valid CAS Registry Number.
1231952-71-8Relevant articles and documents
THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS
-
Page/Page column 68; 69, (2010/08/05)
Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.